Logo image of JAN

JANONE INC (JAN) Stock Fundamental Analysis

NASDAQ:JAN - Nasdaq - US47089W1045 - Common Stock - Currency: USD

2.23  +0.09 (+4.21%)

Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to JAN. JAN was compared to 195 industry peers in the Pharmaceuticals industry. JAN may be in some trouble as it scores bad on both profitability and health. JAN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

JAN had negative earnings in the past year.
In the past year JAN has reported a negative cash flow from operations.
In the past 5 years JAN reported 4 times negative net income.
JAN had negative operating cash flow in 4 of the past 5 years.
JAN Yearly Net Income VS EBIT VS OCF VS FCFJAN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M 10M -10M -15M

1.2 Ratios

JAN's Return On Assets of -107.89% is on the low side compared to the rest of the industry. JAN is outperformed by 83.08% of its industry peers.
JAN has a Return On Equity of -262.72%. This is in the lower half of the industry: JAN underperforms 76.92% of its industry peers.
Industry RankSector Rank
ROA -107.89%
ROE -262.72%
ROIC N/A
ROA(3y)-43.38%
ROA(5y)-41.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
JAN Yearly ROA, ROE, ROICJAN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 -200 -300

1.3 Margins

JAN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
JAN Yearly Profit, Operating, Gross MarginsJAN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 -40

1

2. Health

2.1 Basic Checks

JAN does not have a ROIC to compare to the WACC, probably because it is not profitable.
JAN has more shares outstanding than it did 1 year ago.
JAN has more shares outstanding than it did 5 years ago.
The debt/assets ratio for JAN is higher compared to a year ago.
JAN Yearly Shares OutstandingJAN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M
JAN Yearly Total Debt VS Total AssetsJAN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

JAN has an Altman-Z score of -3.96. This is a bad value and indicates that JAN is not financially healthy and even has some risk of bankruptcy.
JAN has a worse Altman-Z score (-3.96) than 60.00% of its industry peers.
A Debt/Equity ratio of 0.14 indicates that JAN is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.14, JAN is in line with its industry, outperforming 46.15% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z -3.96
ROIC/WACCN/A
WACC9.51%
JAN Yearly LT Debt VS Equity VS FCFJAN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M 20M

2.3 Liquidity

A Current Ratio of 0.15 indicates that JAN may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.15, JAN is doing worse than 98.46% of the companies in the same industry.
JAN has a Quick Ratio of 0.15. This is a bad value and indicates that JAN is not financially healthy enough and could expect problems in meeting its short term obligations.
JAN has a worse Quick ratio (0.15) than 97.95% of its industry peers.
Industry RankSector Rank
Current Ratio 0.15
Quick Ratio 0.15
JAN Yearly Current Assets VS Current LiabilitesJAN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

0

3. Growth

3.1 Past

The earnings per share for JAN have decreased strongly by -163.18% in the last year.
The Revenue for JAN has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-163.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-110.79%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
JAN Yearly Revenue VS EstimatesJAN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

0

4. Valuation

4.1 Price/Earnings Ratio

JAN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
JAN Price Earnings VS Forward Price EarningsJAN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JAN Per share dataJAN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

JAN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

JANONE INC

NASDAQ:JAN (7/12/2024, 8:00:02 PM)

2.23

+0.09 (+4.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-22 2024-05-22/amc
Earnings (Next)08-15 2024-08-15/amc
Inst Owners5.8%
Inst Owner Change48.61%
Ins Owners1.88%
Ins Owner Change0%
Market Cap26.02M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.41
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.97
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)-0.13
OCFYN/A
SpS0
BVpS0.65
TBVpS-0.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -107.89%
ROE -262.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.38%
ROA(5y)-41.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.15
Quick Ratio 0.15
Altman-Z -3.96
F-Score1
WACC9.51%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-163.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-110.79%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-18.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y65.58%
FCF growth 3YN/A
FCF growth 5Y-17.16%
OCF growth 1Y47.72%
OCF growth 3YN/A
OCF growth 5Y-18.82%